Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Sana Biotechnology, Inc.
Sana Biotechnology, Inc. News
Aug 4, 2025 - globenewswire.com
Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes
Jun 23, 2025 - globenewswire.com
Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Sana Biotechnology, Inc. Quantitative Score
About Sana Biotechnology, Inc.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Sana Biotechnology, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Sana Biotechnology, Inc. Financials
Table Compare
Compare SANA metrics with: | |||
|---|---|---|---|
Earnings & Growth | SANA | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | SANA | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | SANA | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | SANA | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Sana Biotechnology, Inc. Income
Sana Biotechnology, Inc. Balance Sheet
Sana Biotechnology, Inc. Cash Flow
Sana Biotechnology, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Sana Biotechnology, Inc. Executives
| Name | Role |
|---|---|
| Dr. Steven D. Harr M.D. | President, Chief Executive Officer & Director |
| Mr. Bernard J. Cassidy J.D. | Executive Vice President, General Counsel & Corporate Secretary |
| Dr. Dhavalkumar D. Patel M.D., Ph.D. | Executive Vice President & Chief Scientific Officer |
| Mr. Snehal Patel | Senior Vice President & Chief Technical Officer |
| Ms. Susan Wyrick | Acting Chief Financial Officer, Treasurer, Principal Accounting Officer and Senior Vice President of Finance & Accounting |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Steven D. Harr M.D. | President, Chief Executive Officer & Director | 1970 | 1.01M | |
| Mr. Bernard J. Cassidy J.D. | Executive Vice President, General Counsel & Corporate Secretary | Male | 1955 | 628.62K |
| Dr. Dhavalkumar D. Patel M.D., Ph.D. | Executive Vice President & Chief Scientific Officer | 1961 | -- | |
| Mr. Snehal Patel | Senior Vice President & Chief Technical Officer | Male | -- | |
| Ms. Susan Wyrick | Acting Chief Financial Officer, Treasurer, Principal Accounting Officer and Senior Vice President of Finance & Accounting | Female | 1973 | -- |
Sana Biotechnology, Inc. Insider Trades
| Date | 7 Jul |
| Name | Bishop Hans Edgar |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 7842 |
| Date | 5 Jun |
| Name | Rosiello Robert L. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 115000 |
| Date | 5 Jun |
| Name | Bilenker Joshua H. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 80000 |
| Date | 5 Jun |
| Name | Bishop Hans Edgar |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 80000 |
| Date | 5 Jun |
| Name | Mulligan Richard |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 80000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 7 Jul | Bishop Hans Edgar | Director | Acquired | A-Award | 7842 |
| 5 Jun | Rosiello Robert L. | Director | Acquired | A-Award | 115000 |
| 5 Jun | Bilenker Joshua H. | Director | Acquired | A-Award | 80000 |
| 5 Jun | Bishop Hans Edgar | Director | Acquired | A-Award | 80000 |
| 5 Jun | Mulligan Richard | Director | Acquired | A-Award | 80000 |